Synergy Pharmaceuticals Inc. (SGYP) Forms $2.11 Double Bottom; Last Week QVC Group (QVCA) Coverage

Synergy Pharmaceuticals Inc. (SGYP) formed double bottom with $1.98 target or 6.00% below today’s $2.11 share price. Synergy Pharmaceuticals Inc. (SGYP) has $520.45 million valuation. The stock increased 1.93% or $0.04 during the last trading session, reaching $2.11. About 4.81M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since February 14, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Among 14 analysts covering Liberty Interactive (NASDAQ:QVCA), 12 have Buy rating, 1 Sell and 1 Hold. Therefore 86% are positive. Liberty Interactive had 29 analyst reports since August 6, 2015 according to SRatingsIntel. Citigroup downgraded QVC Group (NASDAQ:QVCA) rating on Thursday, September 28. Citigroup has “Sell” rating and $22.0 target. The firm has “Buy” rating given on Thursday, August 6 by Axiom Capital. The firm has “Outperform” rating given on Wednesday, August 10 by FBN Securities. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 6. The firm has “Buy” rating by KeyBanc Capital Markets given on Wednesday, January 10. The company was maintained on Monday, July 10 by Craig Hallum. UBS maintained QVC Group (NASDAQ:QVCA) on Friday, November 10 with “Buy” rating. The rating was initiated by Bank of America with “Neutral” on Tuesday, September 20. The firm has “Buy” rating by Axiom Capital given on Friday, November 13. The firm earned “Overweight” rating on Tuesday, December 8 by Pacific Crest. See QVC Group (NASDAQ:QVCA) latest ratings:

10/01/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $28.0 Maintain
03/01/2018 Broker: FBN Securities Rating: Buy Upgrade
10/11/2017 Broker: UBS Rating: Buy Old Target: $27 New Target: $28 Maintain
09/11/2017 Broker: FBR Capital Rating: Buy New Target: $28.0
23/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $27.0 Maintain
28/09/2017 Broker: Citigroup Rating: Sell New Target: $22.0 Downgrade
14/09/2017 Broker: DA Davidson Rating: Buy New Target: $33 Initiates Coverage On

QVC Group markets and sells various consumer products primarily through live merchandise-focused televised shopping programs, Internet, and mobile applications. The company has market cap of $13.28 billion. The company’s Websites offers home, apparel, beauty, accessories, jewelry, and electronics products. It has a 24.75 P/E ratio. It also operates as an online retailer of women’s, children’s, and men’s apparel, and children’s merchandise; and kitchen accessories and home décor products, as well as retails its products through catalogs, and brick-and-mortar stores.

The stock increased 1.74% or $0.47 during the last trading session, reaching $27.45. About 2.34 million shares traded. QVC Group (NASDAQ:QVCA) has declined 6.46% since February 14, 2017 and is downtrending. It has underperformed by 23.16% the S&P500.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on March, 7. They expect $-0.20 EPS, up 35.48% or $0.11 from last year’s $-0.31 per share. After $-0.22 actual EPS reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals has $20 highest and $2.5 lowest target. $9.61’s average target is 355.45% above currents $2.11 stock price. Synergy Pharmaceuticals had 40 analyst reports since August 25, 2015 according to SRatingsIntel. As per Monday, January 8, the company rating was maintained by H.C. Wainwright. As per Monday, June 26, the company rating was maintained by BTIG Research. Cantor Fitzgerald maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Wednesday, September 27 with “Buy” rating. The company was downgraded on Friday, December 18 by Citigroup. The firm earned “Buy” rating on Thursday, January 25 by Cantor Fitzgerald. The firm has “Buy” rating given on Thursday, November 9 by Cantor Fitzgerald. The rating was maintained by Oppenheimer on Thursday, August 10 with “Buy”. TH Capital reinitiated the stock with “Buy” rating in Thursday, October 29 report. The rating was initiated by Oppenheimer with “Outperform” on Thursday, January 5. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, June 1.